8-K current report · filed Nov 12, 2026

Erasca, Inc. (ERAS) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1ERAS overview

Short answer

Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the three months ended September 30, 2026.

Erasca, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the three months ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1, relevant for assessing Erasca’s cash runway and development funding needs

Item EX-99.1 · Exhibit EX-99.1

  • ERAS-0015 received FDA Fast Track for metastatic pancreatic cancer, enabling closer FDA interaction but not increasing approval probability
  • Three potentially registration-enabling trials remain targeted: pancreatic cancer and NSCLC programs beginning 2027
  • Cash, equivalents and marketable securities reached $947.8 million, up from $341.8 million at December 31, 2025
  • Quarterly R&D expense rose to $47.2 million from $22.5 million, reflecting accelerated clinical and preclinical development
  • Quarterly net loss widened to $51.3 million, or $(0.15) per share, from $30.6 million, or $(0.11) per share

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Erasca, Inc. 8-K filings

Get the next ERAS 8-K as it lands

Follow ERAS for push alerts, or ask the research agent what this filing means.